Claims
- 1. A process for the preparation of a δ-lactone of the formula:
- 2. The process of claim 1, wherein R1 is undecyl and R2 is hexyl.
- 3. The process of claim 2, wherein Y is bromide.
- 4. The process of claim 3, wherein Z is selected from the group consisting of morpholino amide, N,O-dimethylhydroxylamino amide, nitrile, acid chloride, pivaloyl anhydride, methyl ester, ethyl ester and t-butyl ester.
- 5. The process of claim 4, wherein said reactive species generating reagent is magnesium.
- 6. The process of claim 4, wherein said reactive species generating reagent is a Grignard reagent.
- 7. The process of claim 6, wherein said Grignard reagent is tert-butyl magnesium chloride or tert-butyl magnesium bromide.
- 8. The process of claim 6, wherein the ratio of said Grignard reagent to said α-halo ester is from about 2:1 to about 5:1.
- 9. The process of claim 1 further comprising the step of adding an additive selected from the group consisting of trapping agents, metal activators, rate enhancers, and mixtures thereof.
- 10. The process of claim 1 further comprising the step of producing said α-halo ester, wherein said α-halo ester producing step comprises contacting a β-hydroxy compound of the formula:
- 11. The process of claim 10, wherein said δ-lactone and said δ-hydroxy compound have (R)-stereoconfiguration.
- 12. The process of claim 11 further comprising the step of enantioselectively producing said β-hydroxy compound by enantioselective reduction of a β-keto compound of the formula:
- 13. The process of claim 12, wherein said enantioselective reduction of said β-keto compound produces said β-hydroxy compound in an enantiomeric excess of at least about 90%.
- 14. The process of claim 12, wherein said chiral hydrogenation catalyst is a compound of the formula RuCl2((R)-MeOBIPHEP).
- 15. The process of claim 12, wherein said chiral hydrogenation catalyst is the product produced by contacting a ruthenium diacetate of the formula Ru(OAc)2((R)-MeOBIPHEP) with a halide source, wherein said halide source is selected from the group consisting of alkaline metal halides and hydrohalides.
- 16. The process of claim 15, wherein the molar ratio of said halide source to said ruthenium diacetate is at least about 20:1.
- 17. A process for producing (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one comprising contacting an α-halo ester of the formula:
- 18. The process of claim 17, wherein Z is selected from the group consisting of morpholino amide, N,O-dimethylhydroxylamino amide, nitrile, acid chloride, pivaloyl anhydride, methyl ester, ethyl ester and t-butyl ester.
- 19. The process of claim 17, wherein said reactive species generating reagent is magnesium.
- 20. The process of claim 17, wherein said reactive species generating reagent is a Grignard reagent.
- 21. The process of claim 20, wherein said Grignard reagent is tert-butyl magnesium chloride or tert-butyl magnesium bromide.
- 22. The process of claim 20, wherein the ratio of said Grignard reagent to said α-halo ester is from about 2:1 to about 5:1.
- 23. The process of claim 17 further comprising the step of adding an additive selected from the group consisting of trapping agents, metal activators, rate enhancers, and mixtures thereof.
- 24. The process of claim 17 further comprising the step of producing said α-halo ester, wherein said α-halo ester producing step comprises contacting a (R)-β-hydroxy compound of the formula:
- 25. The process of claim 24 further comprising the step of enantioselectively producing said (R)-β-hydroxy compound by enantioselective reduction of a β-keto compound of the formula:
- 26. The process of claim 25, wherein said enantioselective reduction produces said β-hydroxy compound in an enantiomeric excess of at least about 90%.
- 27. The process of claim 25, wherein said chiral hydrogenation catalyst is a compound of the formula RuCl2((R)-MeOBIPHEP).
- 28. The process of claim 25, wherein said chiral hydrogenation catalyst is the product produced by contacting a ruthenium diacetate of the formula Ru(OAc)2((R)-MeOBIPHEP) with a halide source, wherein said halide source is selected from the group consisting of alkaline metal halides and hydrohalides.
- 29. The process of claim 28, wherein the molar ratio of said halide source to said ruthenium diacetate is at least about 20:1.
- 30. A process for producing (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one comprising:
(a) enantioselectively reducing a β-keto compound of the formula: 55 to produce a (R)-β-hydroxy compound of the formula: 56(b) contacting said (R)-β-hydroxy compound with an α-halo activated carbonyl compound of the formula: 57 in the presence of a base under conditions sufficient to produce an α-halo ester of the formula: 58(c) contacting said α-halo ester with a reactive species generating reagent selected from the group consisting of Grignard reagents, metal and mixtures thereof under conditions sufficient to produce said (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, wherein Z is nitrile or a moiety of the formula —C(═O)W; W is C1-C6 alkoxide, C6-C20 aryloxide, C7-C20 arylalkoxide, halide, C1-C6 carboxylate or a moiety of the formula —NR3R4; each of R3 and R4 is independently C1-C6 alkyl, C6-C20 aryl, C7-C20 arylalkyl, C1-C6 alkoxide, C6-C20 aryloxide, C7-C20 arylalkoxide or R3 and R4 together form a moiety of the formula —(CR5R6)a-Q-(CR7R8)b—; each of R5, R6, R7 and R8 is independently H or C1-C6 alkyl, C6-C20 aryl, C7-C20 arylalkyl; Q is O, NR9 or S; X is Br or Cl; R9 is H, an amine protecting group, C1-C6 alkyl, C6-C20 aryl or C7-C20 arylalkyl; and each of a and b is independently an integer from 1 to 4.
- 31. The process of claim 30, wherein Z is selected from the group consisting of morpholino amide, N,O-dimethylhydroxylamino amide, nitrile, acid chloride, pivaloyl anhydride, methyl ester, ethyl ester and t-butyl ester.
- 32. The process of claim 30, wherein said reactive species generating reagent is a Grignard reagent.
- 33. The process of claim 32, wherein said Grignard reagent is tert-butyl magnesium chloride or tert-butyl magnesium bromide.
- 34. The process of claim 30, wherein said enantioselective reduction comprises hydrogenation of said β-keto compound in the presence of a chiral hydrogenation catalyst of the formula RuCl2((R)-MeOBIPHEP).
- 35. The process of claim 34, wherein said enantioselective reduction produces said β-hydroxy compound in an enantiomeric excess of at least about 90%.
- 36. The process of claim 34, wherein said chiral hydrogenation catalyst is the product produced by contacting a ruthenium diacetate of the formula Ru(OAc)2((R)-MeOBIPHEP) with a halide source selected from the group consisting of alkaline metal halides, hydrohalides, and mixtures thereof.
- 37. The process of claim 36, wherein the molar ratio of said halide source to said ruthenium diacetate is at least about 20:1.
- 38. A compound of the formula:
- 39. The compound according to claim 38 of the formula:
- 40. The compound of claim 39, wherein Z is an ester.
- 41. The compound of claim 40, wherein Z is a moiety of the formula —C(═O)OMe or —C(═O)Ot-Bu.
- 42. A process for producing δ-ketoester of the formula:
- 43. The process of claim 42, wherein X is Chloride, R1 is undecyl, and R10 is methyl.
- 44. The process of claim 43, wherein said magnesium alkoxide is magnesium methoxide and said first and said second alcohols are methanol.
- 45. The process of claim 44 further comprising a reaction solvent.
- 46. The process of claim 45, wherein said reaction solvent is toluene.
- 47. The process of claim 46, wherein the reaction temperature of said step (a) is at least about 45° C.
- 48. The process of claim 47 further comprising removing said methanol by azeotropic distillation.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/180,560, filed Feb. 4, 2000, which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60180560 |
Feb 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09668834 |
Sep 2000 |
US |
Child |
10364536 |
Feb 2003 |
US |